MAP2K7 and cancer: Recently, two highly selective MEK inhibitors, namely trametinib (Trame) and cobimetinib (Cobi), have been introduced, either alone or in combination with BRAF inhibitors, in the treatment of advanced cancers, including metastatic melanoma [11].